

# NITEESH K. CHOUDHRY, M.D., Ph.D.

**DATE PREPARED:** March 14, 2016

**Office Address:** Division of Pharmacoepidemiology and Pharmacoeconomics  
Department of Medicine, Brigham and Women's Hospital  
1620 Tremont Street, Suite 3030, Boston, MA 02120

## Education

1990-1992		Microbiology and Immunology	McGill University, <i>Montreal, Canada</i>
1992-1996	M.D.	Medicine	University of Toronto, <i>Toronto, Canada</i>
2000-2005	Ph.D.	Health Care Policy	Harvard University, <i>Cambridge, MA</i>

## Postdoctoral Training

07/1996- 06/1999	Resident	Internal Medicine	University of Toronto
07/1999- 06/2000	Chief Resident	Internal Medicine	Toronto General and Western Hospitals <i>Toronto, Canada</i>
07/2003- 06/2005	Fellow	Pharmaceutical Policy Research	Harvard Medical School, <i>Boston, MA</i>

## Faculty Academic Appointments

07/2000- 06/2001	Instructor	Medicine	University of Toronto
07/2001- 06/2004	Lecturer	Medicine	University of Toronto
07/2001- 06/2004	Special Lecturer	Law	University of Toronto
01/2003- 06/2003	Instructor	Medicine	Harvard Medical School
07/2003- 06/2004	Instructor	Ambulatory Care and Prevention (now Population Medicine)	Harvard Medical School
07/2004- 03/2006	Instructor	Medicine	Harvard Medical School
04/2006- 08/2011	Assistant Professor	Medicine	Harvard Medical School
09/2011-	Associate Professor	Medicine	Harvard Medical School

## Appointments at Hospitals/Affiliated Institution

### Past

07/2000- 06/2004	Associate Physician	Department of Medicine, Division of General Internal Medicine	Toronto General and Western Hospitals
---------------------	------------------------	------------------------------------------------------------------	---------------------------------------

### Current

01/2003-	Associate Physician	Department of Medicine, Division of General Internal Medicine	Brigham and Women's Hospital <i>Boston, MA</i>
07/2004-	Associate Physician	Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics	Brigham and Women's Hospital

### **Other Professional Positions**

2007-	Senior Clinical Consultant, Independent Drug Information Service	Alosa Foundation, <i>Boston, MA</i>
2014-	Board of Directors	Alosa Foundation
2015-	Board of Directors	Population Services International, <i>Washington, DC</i>

### **Major Administrative Leadership Responsibilities**

2001-2002	Director, Internal Medicine Clerkship Program	Toronto General Hospital
2001-2002	Coordinator, Internal Medicine Student Electives	Toronto General Hospital
2009-	Director, Research Operations, Division of Pharmacoepidemiology and Pharmacoeconomics	Brigham and Women's Hospital
2013-2104	Course Director, <i>An Introduction to Comparative Effectiveness, Cost-Effectiveness and Implementation Research</i>	Harvard Catalyst, <i>Boston, MA</i>
2013-	Executive Director, Center for Healthcare Delivery Sciences	Department of Medicine, Brigham and Women's Hospital
2014-	Director, Implementation Research and Education	Harvard Catalyst, <i>Boston, MA</i>
2015-	Course Director, <i>Translating Effective Interventions into Practice</i>	Harvard Catalyst
2016-	Course Director, <i>Comparative Effectiveness Research</i>	Harvard Catalyst

### **Committee Service**

#### Local

1990-1992	Admissions and Scholarships Committee	McGill University
1991-1992	Academic Planning and Policy Subcommittee on Teaching and Learning	McGill University
1992-1994	Clerkship Curriculum Committee	University of Toronto Faculty of Medicine
1992-1995	Curriculum Subcommittee on Examinations and Assessments	University of Toronto Faculty of Medicine
1993-1994	Task Force on Grading Systems in the New Curriculum, Faculty of Medicine	University of Toronto Faculty of Medicine
1998-2000, 2001-2002	Residency Training Committee, Department of Medicine	Toronto General and Western Hospitals
2001-2002	Residency Selection Committee	University of Toronto Faculty of Medicine

2001-2002	Clinical Clerkship Committee	University of Toronto Faculty of Medicine
2001-2002	Clerkship Committee	Toronto General and Western Hospitals
2004-2005	Strategic Planning Committee, Hospitalist Program	Brigham and Women's Hospital
2005-2011	Residency Redesign Committee, Department of Medicine	Brigham and Women's Hospital
2006-	Residency Selection Committee, Department of Medicine	Brigham and Women's Hospital
2007-2008	Clinical Research Working Group, Department of Medicine	Brigham and Women's Hospital
2007-2012	Inpatient Residency Redesign Committee	Brigham and Women's Hospital
2008-2010	Clinical Research Advisory Committee, Department of Medicine	Brigham and Women's Hospital
2010-2011	Committee on Comparative Effectiveness	Harvard Medical School
2010-2014	Research Advisory Committee, Department of Medicine	Brigham and Women's Hospital
2011-2012	Advisory Taskforce on Residency-Wide Research Projects, Department of Medicine	Brigham and Women's Hospital
2012-	Chair, Faculty Search Committee, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine	Brigham and Women's Hospital

Regional

2004	Medical Quality Indicators Committee 2004	Ontario Hospital Report Research Collaborative Chair
------	----------------------------------------------	---------------------------------------------------------

National

2014-	Drug Safety and Risk Management Advisory Committee	U.S. Food and Drug Administration (FDA)
2014-	Executive Committee, BEST-CLI (Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia) Trial	National Health, Lung and Blood Institute
2014-	Executive Committee, ARTEMIS (Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study) Trial	Duke University

International

2015-	Executive Committee, SECURE (Secondary prevention of CV disease in the elderly) Trial	CNIC Fundacion Centro Nacional de Investigacion Cardiovasculares Carlos III, Madrid, Spain and Mount Sinai Hospital, New York, NY
-------	---------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------

**Professional Societies**

2000-	Fellow, Royal College of Physicians and Surgeons of Canada
2000-	American College of Physicians
2000-	University of Toronto Joint Centre for Bioethics

2000-2006 Canadian Medical Association  
 2005- Society of General Internal Medicine  
 2006- Member, Abstract Selection Committee  
 2005- International Society of Pharmacoepidemiology  
 2012 Member, International Steering Group, Asian Conference on Pharmacoepidemiology  
 2013- Vice Chair, Medication Adherence Scientific Interest Group  
 2005- Academy Health  
 2006- Massachusetts Medical Society  
 2011- International Society for Pharmacoeconomics and Outcomes Research

**Grant Review Activities**

2009	Catalyst Grant Review Committee	Harvard University
	2009	<i>Ad hoc</i> Member
2009-2012	Drug Innovation Fund Grants	Ontario Ministry of Health and Long-Term Care
	2009-2012	Permanent Member
2010-	Support for Excellence in Educational Development (S.E.E.D.) Grants	Brigham and Women’s Hospital, Department of Medicine
	2010-	Permanent member
2012	Large-Scale Applied Research Project Competition in Genomics and Personalized Health	Genome Canada
	2012	College of Reviewers
2013-	Health Services Research and Development Scientific Merit Review Committee	Veterans Health Administration
	2013-	<i>Ad hoc</i> Member
2014-	National Institute of Diabetes and Digestive and Kidney Diseases R18/R34 Study Section	National Institutes of Health
	2014-	<i>Ad hoc</i> Member
2015-	National Health, Lung and Blood Institute Clinical Trials Review Committee Study Section	National Institutes of Health
	2015-	Permanent Member

**Editorial Activities**

*Ad hoc reviewer*

The Lancet  
 British Medical Journal  
 Journal of Health Services Research and Policy  
 Archives of Internal Medicine  
 Health Affairs  
 Health Policy

International Journal for Quality in Health Care  
 Journal of Clinical Epidemiology  
 New England Journal of Medicine  
 Annals of Internal Medicine  
 Drug Safety  
 Health Services Research  
 Canadian Medical Association Journal  
 Journal of the American Medical Association  
 American Heart Journal  
 Circulation: Cardiovascular Quality and Outcomes  
 American Journal of Managed Care  
 Journal of General Internal Medicine  
 Pharmacoepidemiology and Drug Safety  
 Pharmacoeconomics  
 Journal of the American College of Cardiology

#### Other Editorial Roles

1995-1996	Associate Editor	Medical Council of Canada Qualifying Exam Review Notes, 12 <sup>h</sup> Ed
2011-2013	Deputy Editor	Journal of General Internal Medicine
2012-	Editorial Board	Health Care
2013-2014	Editorial Board	Current Cardiology Reports

#### **Honors and Prizes**

1990-1992	R.E. Powell Scholarship	McGill University	Academic achievement
1990-1992	Dean's Honor List	McGill University	Academic achievement
1990-1992	Canada Science Scholarship	Government of Canada	Academic achievement
1991	Summer Student Fellowship	Juvenile Diabetes Foundation	Academic achievement
1992-1993	Life Science Summer Student Fellowship	University of Toronto	Academic achievement
1993-1996	Dean's Honor List, Faculty of Medicine	University of Toronto	Academic achievement
1994	Jane and Howard O. Jones Scholarship, Faculty of Medicine	University of Toronto	Academic achievement
1995	Frankal Memorial Award, Faculty of Medicine	University of Toronto	Academic achievement
1996	Dr. Fred Douglas Memorial Award, Faculty of Medicine	University of Toronto	Academic achievement
1996	Faculty of Medicine Resident Research Competition, 2nd Prize	University of Toronto	Research excellence
1998	Nomination, D.H. Cowan Award for Teaching	Sunnybrook Health Science Centre, <i>Toronto, Canada</i>	Teaching excellence
1999-2000	Detweiler Fellowship	Royal College of Physicians and Surgeons of Canada	Academic achievement
2000	Fulbright Scholarship (Declined)	Fulbright Scholarship Program	Academic achievement

2000	K.J.R. Wightman Award for Research in Biomedical Ethics	Royal College of Physicians and Surgeons of Canada	Research excellence
2000	M.F.X. Glynn Award for Excellence in Clinical Teaching	Toronto General Hospital Department of Medicine	Teaching excellence
2000	Wightman-Berris Academy Award for Excellence in Undergraduate Teaching	University of Toronto	Teaching excellence
2000	Nomination, Teaching Award	Professional Association of Interns and Resident of Ontario	Teaching excellence
2000-2004	Frank Knox Memorial Fellowship	Harvard University	Academic achievement
2002	New Faculty Excellence in Teaching Award	Toronto General Hospital Department of Medicine	Teaching excellence
2002	Nomination, Wightman-Berris Award for Excellence in Postgraduate Teaching	University of Toronto	Teaching excellence
2003	Winner, Health Caucus Essay Contest	Harvard Medical School	Research excellence
2003	Nomination, Aikins Award for Teaching Excellence, Faculty of Medicine	University of Toronto	Teaching excellence
2003-2005	Pharmaceutical Policy Research Fellowship	Harvard Medical School	Academic achievement
2004	Nesson Award for Collaboration (with BWH Hospitalist Program)	Partners Community Health Care	Clinical service
2005	Mack Lipkin, Sr. Research Award	Society of General Internal Medicine	Research excellence
2005	Awarded Membership to Society of Teaching Scholars	Brigham and Women's Hospital	Teaching excellence
2006	Excellence in Teaching Award	Brigham and Women's Hospital Hospitalist Program	Teaching excellence
2007	Nomination, Faculty Prize for Excellence in Teaching	Harvard Medical School	Teaching excellence
2008	Distinguished Faculty Mentor Award, Department of Medicine	Brigham and Women's Hospital	Mentoring
2008	Nomination, Faculty Prize for Excellence in Teaching	Harvard Medical School	Teaching excellence
2008,2009	Peer-Reviewer Award	Annals of Internal Medicine	
2010	Jean Jackson Distinguished Bedside Teacher Award, Department of Medicine	Brigham and Women's Hospital	Teaching excellence
2011	Nomination, Bernard Lown Award for Excellence in Teaching	Brigham and Women's Hospital	Teaching excellence
2011	Honor Roll, Partners Outstanding Clinical Teacher Award	Partners Healthcare	Teaching excellence

2012	Award for Excellence in Application in Pharmacoeconomics and Health Outcomes Research	International Society for Pharmacoeconomics and Outcomes Research	Research excellence
2012	Annual Research Award 2 <sup>nd</sup> prize	National Institutes of Health Care Management	Research excellence
2012	Best Abstract Award	AcademyHealth	Research excellence
2013	Best Abstract Award	AcademyHealth	Research excellence
2014	Distinguished Faculty Mentor Award, Department of Medicine	Brigham and Women's Hospital	Mentoring
2015	George W. Thorn Award, Department of Medicine	Brigham and Women's Hospital	Teaching excellence

## **REPORT OF LOCAL TEACHING AND TRAINING**

### **Teaching of Students in Courses**

#### University of Toronto

1999-2000	<b>University of Toronto: Internal Medicine Seminar Series, Seminar Leader</b>		
	4th year medical students		3 hours per week for 36 weeks
1999-2000	<b>University of Toronto: Internal Medicine Seminar Series, Seminar Leader</b>		
	3rd year medical students		1 hour per week for 18 weeks
1999-2000	<b>University of Toronto: Art and Science of Physical Examination Course, Instructor and Examiner</b>		
	1st year medical students		3 hours per week for 40 weeks
2001-2002	<b>University of Toronto: Physical Examination Series, Course Instructor</b>		
	4th year medical students		1 hour per week for 36 weeks
2001-2002	<b>University of Toronto: Physical Examination Series, Course Instructor</b>		
	3rd year medical students		1 hour per week for 36 weeks
2001-2002	<b>University of Toronto: Evidence-Based Medicine Section, Determinants of Community Health, Seminar Leader</b>		
	2nd year medical students		2 hours per week for 3 weeks
2001-2002	<b>University of Toronto: Internal Medicine Written and Oral Examinations, Author, Examiner and Invigilator</b>		
	4th year medical students		Contact time: 20 hours Preparation time: 80 hours
2002-2003	<b>University of Toronto: Conflicts of Interest in Medicine: Evidence, Public Policy and the Law, Instructor</b>		
	Law students (JD and LLM programs)		6 hours per day for 2 weeks per year

Harvard Medical School

2003-2005	<b>HMS (Harvard Medical School) IN710M.23 Introduction to Clinical Medicine, Medical Preceptor</b> 2nd year medical students	2 hours per week for 12 weeks
2006-2011	<b>HMS IN710M.23 Introduction to Clinical Medicine, Lecturer, The comprehensive physical examination</b> 2nd year medical students	2 hours per year
2007, 2009, 2014	<b>HMS Principles of Pharmacology for the Clinical Investigator, Pharmacoepidemiology and Pharmacoeconomics Module, Seminar Leader</b> Graduate students	2 hours per year

Harvard School of Public Health

2012-2015	<b>HSPH (Harvard School of Public Health) EPI235: Epidemiologic Methods in Health Services Research, Lecturer, Pragmatic quality improvement trials</b> Graduate students	1 hour per year
2012	<b>HSPH EPI286: Advanced Pharmacoepidemiology, Lecturer, Studying non-adherence</b> Graduate students	2 hour lecture
2013	<b>HSPH HPM277: Current Issues in Health Policy, Lecturer, Medications and health policy</b> Graduate students	2 hour lecture
2013-2015	<b>HSPH EPI286: Advanced Pharmacoepidemiology, Lecturer, Database randomized trials</b> Graduate students	2 hour lecture per year
2016-	<b>HSPH EPI235: Epidemiologic Methods in Health Services Research, Lecturer, An introduction to non-adherence</b> Graduate students	1 hour

Boston University

2013-2015	<b>Boston University: Advanced Pharmacoepidemiology, Lecturer, Database randomized trials</b> Graduate students	2.5 hour lecture
-----------	--------------------------------------------------------------------------------------------------------------------	------------------

Massachusetts Institute of Technology

2016	<b>MIT Sloan School of Management, Lecturer, Medication</b> Graduate students	1.5 hour lecture
------	----------------------------------------------------------------------------------	------------------



## Formal Teaching of Residents, Clinical Fellows and Research Fellows

### University of Toronto

1999-2000	<b>Royal College Scenario Rounds, Instructor</b> Internal medicine residents	Toronto General Hospital 1 hour per week for 40 weeks
1999-2000 2001-2002	<b>Morning Report, Discussant</b> Internal medicine residents	Toronto General Hospital 1 hour per week for 52 weeks per year
2000	<b>Stable Coronary Artery Disease</b> (Internal Medicine Outpatient Clinic), <i>Lecturer</i> Internal medicine residents	Toronto General Hospital 1 hour lecture for 2 weeks
2001-2002	<b>Royal College Physical Examination Rounds, Instructor</b> Internal medicine residents	Toronto General Hospital 1 hour per week for 6 weeks
2001-2002	<b>Pneumonia</b> (Housestaff Noon Lecture Series), <i>Lecturer</i> Internal medicine residents	Toronto General Hospital 1 hour per week for 6 weeks
2002	<b>Questioning Skills</b> (Teaching to Teach Retreat), <i>Lecturer</i> Internal medicine residents	University of Toronto 2 hour seminar

### Harvard Medical School

2003-2004	<b>Using the Medical Evidence in Clinical Decision-Making, Course Designer/Lecturer</b> Internal medicine residents	Brigham and Women's Hospital 1 hour lectures for 10 weeks
2003-	<b>Morning Report, Discussant</b> Internal medicine residents	Brigham and Women's Hospital 1 hour every 2 months
2004	<b>Resident Sign-Out Rounds, Discussant</b> Internal medicine residents	Brigham and Women's Hospital 1 hour seminar on 3 occasions
2004-2006	<b>Pharmacoepidemiology Combined Hospitalist Rounds, Course Coordinator/Lecturer</b> Internal medicine residents	Brigham and Women's Hospital 1 hour per month
2004-2014	<b>Resident Journal Club, Discussant</b> Internal medicine residents	Brigham and Women's Hospital 1 hour seminar every 3 months

2006	<b>Prevention of cardiovascular disease with antiplatelet drugs</b> (Combined Hospitalist Rounds), <i>Lecturer</i> Internal medicine residents	Brigham and Women's Hospital 1 hour lecture
2006	<b>Are all statins created equal?</b> (Combined Hospitalist Rounds), <i>Lecturer</i> Internal medicine residents	Brigham and Women's Hospital 1 hour lecture
2007	<b>Sticking to the evidence on antiplatelet drugs</b> (Combined Hospitalist Rounds), <i>Lecturer</i> Internal medicine residents	Brigham and Women's Hospital 1 hour lecture
2007	<b>Should we not be aiming for tight glucose control in patients with diabetes?</b> (Combined Hospitalist Rounds), <i>Lecturer</i> Internal medicine residents	Brigham and Women's Hospital 1 hour lecture
2007-	<b>Morning Report</b> , <i>Discussant</i> Internal medicine residents	Faulkner Hospital (now Brigham and Women's Faulkner Hospital) 1 hour approximately 3 times per year
2007-2011	<b>Physical Examination Rounds</b> , <i>Instructor</i> Internal medicine residents	Faulkner Hospital 1 hour session twice per year
2007	<b>Should we not be aiming for tight glucose control in patients with diabetes?</b> (Combined Hospitalist Rounds), <i>Lecturer</i> Internal medicine residents	Brigham and Women's Hospital 1 hour lecture
2008	<b>The cost-effectiveness of antiplatelet drugs for the prevention of major vascular events</b> (Housestaff Noon Conference), <i>Lecturer</i> Internal medicine residents	Brigham and Women's Hospital 1 hour lecture
2008	<b>Choosing the right AIC goal</b> (Combined Hospitalist Rounds), <i>Lecturer</i> Internal medicine residents	Brigham and Women's Hospital 1 hour lecture
2008	<b>Morning Report</b> , <i>Discussant</i> Internal medicine residents	VA West Roxbury 1 hour lecture
2008-2012	<b>Professor's Rounds</b> , <i>Instructor</i> Internal medicine residents	Brigham and Women's Hospital 1 hour session twice per year

2009	<b>An introduction to cost-effectiveness</b> (Housestaff Noon Conference), <i>Lecturer</i> Internal medicine residents	Brigham and Women's Hospital  1 hour lecture
2009-2015	<b>An evidence-based approach to syncope</b> (Housestaff Noon Conference), <i>Lecturer</i> Internal medicine residents	Brigham and Women's Hospital  1 hour lecture
2010	<b>Resident Research Report</b> , <i>Discussant</i> Internal medicine residents	Brigham and Women's Hospital 1 hour session
2010	<b>The consequences and costs of prescription drug use in real-world settings</b> , <i>Lecturer</i>  Clinical Investigator Training Program fellows	Harvard-Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology  2.5 hour session
2011	<b>Adherence to essential medications</b> , <i>Lecturer</i> Primary care residents	Brigham and Women's Hospital 1 hour lecture
2011-2013	<b>An evidence-based approach to syncope</b> (Housestaff Noon Conference), <i>Lecturer</i> Internal medicine residents	Veterans Administration (VA) Medical Center, <i>West Roxbury, MA</i> 1 hour lecture
2012	<b>Should essential drugs be "FREEE"?: Using empirical methods to answer policy relevant questions</b> , <i>Lecturer</i> Primary care residents	Brigham and Women's Hospital  1 hour lecture
2012	<b>Paying less for what works more: enhancing value in pharmacy benefit design</b> , <i>Lecturer</i> Management leadership track residents	Brigham and Women's Hospital  1 hour lecture
2013	<b>Clinical trials in insurance systems</b> , <i>Lecturer</i> Internal medicine residents	Brigham and Women's Hospital 1 hour lecture
2013	<b>Antithrombotics for atrial fibrillation: an evidence-based approach</b> , <i>Lecturer</i> Internal medicine residents	Faulkner Hospital  1 hour lecture

### **Clinical Supervisory and Training Responsibilities**

#### University of Toronto

1999-2000-2000-2001	<b>Ambulatory Internal Medicine</b> <i>Clinic Preceptor/Attending Physician</i>	Toronto General and Western Hospitals	One half-session per week
2001-2002	<b>Inpatient Internal Medicine Service</b> <i>Attending Physician</i>	Toronto General Hospital	10 months

2001- 2002	<b>Medical Consultation Service</b> <i>Attending Physician</i>	Toronto General Hospital	2 months
---------------	-------------------------------------------------------------------	--------------------------	----------

Harvard Medical School

2003-	<b>ME600M.23 Core Medicine Clerkship I</b> <i>Visiting/Attending</i>	Brigham and Women's Hospital	12 weeks per year
2003-	<b>ME550M.23 Core Medicine Clerkship II</b> <i>Visiting/Attending</i>	Brigham and Women's Hospital	12 weeks per year
2003-	<b>Hospitalist Service and Integrated Teaching Unit</b> <i>Attending Physician</i>	Brigham and Women's Hospital	12 weeks per year

**Formal Teaching of Peers**

*(No presentations below were sponsored by outside entities)*

2001	<b>Understanding the New World of Health Care</b> Understanding the New World of Health Care, <i>Rotman School of Business, University of Toronto and Harvard University Division of Health Policy</i>	Course Facilitator Toronto
2001	<b>Teaching the Physical Examination</b> Teaching Teachers to Teach, <i>Hospitalist Program, Brigham and Women's Hospital</i>	10 one hour lectures Toronto
2006	<b>Pharmacoeconomics in Clinical Trials</b> Clinical Trials: Principles and Practice, <i>Harvard Medical School</i>	Single presentation Boston
2010-	<b>Comparative and Cost-Effectiveness Analysis</b> Introduction to Clinical Investigation, <i>Harvard Catalyst</i>	Single presentation in a recurring course (3 times per year) Boston
2012	<b>An Introduction to Comparative Effectiveness Research</b> Harvard-Portugal Program	Single presentation Boston
2012	<b>An Introduction to Cost-Effectiveness Analysis</b> Harvard-Portugal Program	Single presentation Boston
2012	<b>The New Drugs: Are They Worth It? A Pharmacoeconomic Perspective</b> Thrombosis and Thromboembolism, <i>Harvard Medical School</i>	Keynote speaker Boston
2012	<b>Comparative Effectiveness Research and Cost-Effectiveness Analysis</b> Harvard-China Program, <i>Harvard School of Public Health</i>	Single presentation Boston

2014, 2015	<b>Lost in Translation: developing the science of implementation</b> Global Clinical Scholars Research Training Program (GCSRT), <i>Harvard Medical School</i>	Single presentation and workshop Boston
2014, 2015	<b>T3/T4 Research: An Introduction to Comparative Effectiveness, Cost-Effectiveness and Implementation Research</b> Fundamentals of Clinical and Translational Research, <i>Harvard Catalyst</i>	Four-part lecture in an online course Boston

### Local Invited Presentations

*(No presentations below were sponsored by outside entities)*

2002	<b>Fraud and gaming in the Canadian health care system</b> (Clinical Epidemiology Rounds) University of Toronto Department of Medicine
2003	<b>Cardiopulmonary resuscitation (CPR) for patients labeled Do Not Resuscitate (DNR)</b> (Hospitalist Rounds) Department of Medicine, Brigham and Women's Hospital
2004	<b>Strategies to change prescribing behavior</b> (Research Seminar) Department of Ambulatory Care and Prevention, Harvard Medical School
2004	<b>Health care in US and Canada</b> (Health Policy Panel) Harvard Medical School
2005	<b>Case of the Month, Discussant</b> (Grand Rounds) Department of Medicine, Brigham and Women's Hospital
2005	<b>Clinical Experience: Implications for Medical Licensure</b> (Research Seminar) Dana-Farber Cancer Institute Center for Outcomes and Policy Research
2005	<b>Peri-operative beta-blockade</b> (Hospitalist Journal Club) Department of Medicine, Brigham and Women's Hospital
2005	<b>Teaching on Attending Rounds</b> (Invited lecture) Department of Medicine, Brigham and Women's Hospital
2005	<b>Clinical decision making and anticoagulation for atrial fibrillation</b> (Symposium Lecture) Harvard Medical School Fellowship in Pharmaceutical Policy Research
2006	<b>Prescription drug policy</b> (Panelist) Faculty of Arts and Science
2007	<b>Cost-related drug underuse</b> (Research Seminar) Department of Ambulatory Care and Prevention, Harvard Medical School

- 2008 **Reducing cost-sharing for medications after MI** (Grand Rounds)  
Thrombolysis in MI (TIMI) Study Group, Brigham and Women's Hospital, Harvard Medical School
- 2008 **An approach to improve adherence to evidence-based therapies** (Grand Rounds)  
Cardiology Division, Brigham and Women's Hospital
- 2008 **Improving adherence to evidence-based therapies for patients after myocardial infarction**  
(Grand Rounds)  
Cardiology Division, Massachusetts General Hospital
- 2009 **"A 50 year old female with muscle aches and peripheral edema,"** *Discussant*  
(Clinicopathologic Conference)  
Department of Medicine, Brigham and Women's Hospital
- 2009 **Fire and forget — how medication non-adherence undermines the goals of cardiovascular prevention** (Grand Rounds)  
Cardiology Division, VA West Roxbury
- 2010 **Medication cost and their adverse consequences for adherence to prescription drugs**  
(Research Seminar)  
Division of Rheumatology, Brigham and Women's Hospital
- 2010 **The cost and value of personalized medicine in the era of reform** (Panelist)  
Partners Healthcare Personalized Medicine Conference, Harvard Medical School
- 2011 **Copayments for cardiovascular drugs: is less more than enough?** (Invited lecture)  
Drug Policy Research Group, Department of Population Medicine, Harvard Medical School
- 2011 **Should drugs be FREEEE? Strategies to improve adherence to essential medicines** (Grand Rounds)  
Beth Israel Deaconess Medical Center Division of Primary Care, Boston, MA
- 2012 **How medication non-adherence contributes to the epidemic of chronic disease** (Grand Rounds)  
Faulkner Hospital, Department of Medicine
- 2013 **Non-adherence and the epidemic of chronic disease: lessons for health care delivery redesign** (Invited lecture)  
Department of Population Medicine, Harvard Medical School
- 2014 **Non-adherence and the epidemic of chronic disease: why hospitalists should care and what we can do about it** (Invited lecture)  
Hospitalist Service, Department of Medicine, Brigham and Women's Hospital
- 2014 **"A 26 year-old man with fever,"** *Discussant* (Clinicopathologic Conference)  
Department of Medicine, Brigham and Women's Hospital

- 2016 **Doctors, patients and the healthcare system: a collaborative for addressing non-adherence** (Grand Rounds)  
Joslin Diabetes Center, *Boston, MA*
- 2016 **A quest for simple, scalable solutions for patient and provider engagement** (Invited Lecture)  
Ariadne Labs, *Boston, MA*

### **REPORT OF REGIONAL, NATIONAL, OR INTERNATIONAL INVITED TEACHING AND PRESENTATIONS**

*(No presentations below were sponsored by outside entities)*

#### **Regional**

- 2002 **Performance Measures and Outcomes, and Remuneration Models** (Panelist)  
Workplace Safety and Insurance Board of Ontario, *Toronto*
- 2006 **An evidence-based look at antiplatelet drugs** (Invited Lecture)  
Independent Drug Information Service
- 2006 **Recommendations for the use of antiplatelet drugs** (Invited Lecture)  
Independent Drug Information Service
- 2006 **The comparative effectiveness of statins for vascular disease** (Invited Lecture)  
Independent Drug Information Service
- 2007 **Class effects for antihypertensive drugs** (Invited Lecture)  
Independent Drug Information Service
- 2007 **Efficacy, safety and costs of oral hypoglycemic agents** (Invited Lecture)  
Independent Drug Information Service
- 2007 **Are all antidepressants the same?** (Invited Lecture)  
Independent Drug Information Service
- 2009 **A review of recent clinical trials of antiplatelet drugs** (Invited Lecture)  
Independent Drug Information Service
- 2010 **Which statin should I choose?** (Invited Lecture)  
Independent Drug Information Service
- 2010 **Treating osteoporosis: comparing treatment modalities** (Invited Lecture)  
Independent Drug Information Service
- 2011 **Antithrombotic therapies for atrial fibrillation** (Invited Lecture)  
Independent Drug Information Service

- 2011- **A toolkit for evidence-based medicine** (Invited Lecture)  
National Resource Center for Academic Detailing, *Boston, MA* (Regional and national attendees)
- 2011 **An evidence-based approach to the use of nonsteroidal anti-inflammatory drugs (NSAIDs) for the management of pain** (Invited Lecture)  
Independent Drug Information Service
- 2012 **Is FREEE cheap enough? Addressing the epidemic of non-adherence to essential medications** (Invited lecture)  
Tufts University Institute for Clinical Research and Health Policy Studies, *Boston, MA*
- 2011 **Pharmacotherapy for congestive heart failure** (Invited Lecture)  
Independent Drug Information Service
- 2012 **Evaluating an academic detailing program** (Invited Lecture)  
National Resource Center for Academic Detailing (Regional and national attendees)
- 2012 **Peptic ulcer disease and non-ulcer dyspepsia: what is the evidence?** (Invited Lecture)  
Independent Drug Information Service
- 2012 **Enhancing the validity of academic detailing program evaluations** (Invited Lecture)  
National Resource Center for Academic Detailing (Regional and national attendees)
- 2012 **Antiplatelets for stroke and primary prevention** (Invited Lecture)  
Independent Drug Information Service
- 2013 **Does a spoon full of medicine help the sugar go down?** (Invited Lecture)  
Independent Drug Information Service
- 2013 **Obesity and chronic disease** (Invited Lecture)  
Independent Drug Information Service
- 2013 **Breathing easier: Management of acute exacerbations of chronic obstructive pulmonary disease (COPD)** (Invited Lecture)  
Independent Drug Information Service
- 2014 **The management of a patient with behavioral and psychological symptoms of dementia** (Invited Lecture)  
Independent Drug Information Service
- 2014 **How practitioners and academics can partners for randomized controlled trial (RCTs)** (Invited Lecture/Opening Address)  
Jameel-Poverty Action Lab, Massachusetts Institute of Technology, *Boston, MA*

## National

- 2000 **Does this patient have a diastolic murmur?** (Invited Lecture)  
Physician Services Incorporated Annual Meeting, *Toronto, Canada*



- 2002 **Canadian Health Care Fraud Study** (Invited lecture)  
Canadian Health Care Anti-Fraud Association Annual Meeting, *Toronto, Canada*
- 2002 **K.J.R. Wightman Award Lecture -- CPR for the DNR: the role of the limited aggressive therapy order** (Plenary presentation)  
Royal College of Physicians and Surgeons of Canada Annual Meeting, *Edmonton, Canada*
- 2008 **Strategies to make medications more affordable** (Invited lecture)  
American Thoracic Society Project Committee, *Toronto, Canada*
- 2008 **Innovative ideas in value-based insurance design** (Invited lecture and panelist)  
Robert Wood Johnson Foundation Changes in Health Care Financing and Organization, *Washington, DC*
- 2009 **Cost-related non-adherence** (Invited lecture)  
American Thoracic Society Annual Meeting, *San Diego, CA*
- 2009 **The role of value-based insurance design in reducing health care spending** (Invited lecture)  
Institute of Medicine of the National Academy of Sciences, *Washington, DC*
- 2009 **Value-based benefit design** (Discussant)  
California HealthCare Foundation, *Oakland, CA*
- 2010 **Copayments for cardiovascular drugs: is less more than enough?** (Invited lecture)  
Leonard Davis Institute of Health Economics, University of Pennsylvania, *Philadelphia, PA*
- 2011 **Spending money to make money: the potential value of lowering copayments for cardiovascular drugs** (Invited lecture)  
Program of Public Health, Brown University, *Providence, RI*
- 2011 **Methodology and comparative effectiveness research: It's not just about RCT's** (Invited lecture)  
American Heart Association Annual Meeting, *Orlando, FL*
- 2011 **Full coverage for preventive medications after myocardial infarction** (Plenary – Late Breaking Clinical Trial)  
American Heart Association Annual Meeting, *Orlando, FL*
- 2011 **The MI FREEE Trial** (Invited lecture/discussant)  
Cardiology Division Journal Club, Washington Hospital Center, Georgetown University, *Washington, DC*
- 2012 **Implementing randomized effectiveness trials in large insurance systems** (Invited lecture)  
Agency for Healthcare Research and Quality, *Washington, DC*

- 2012 **Improving adherence to evidence-based cardiovascular medications: opportunities for advocacy and evidence-based policy making** (Invited lecture)  
American Heart Association Advocacy Committee, *Dallas, TX*
- 2012 **Improving adherence to antihypertensive therapies** (Keynote speaker)  
Million Hearts Initiative/American Heart Association, *Washington, DC*
- 2012 **Improving adherence to evidence-based medications: opportunities for community-based settings** (Keynote speaker)  
New England Healthcare Institute, *National Press Club, Washington, DC*
- 2012 **High-risk beneficiaries, medication adherence and activities to support good choices** (Invited speaker)  
Pacific Business Group on Health, *San Francisco, CA*
- 2012 **Predicting the success of value-based insurance designs to improve adherence** (Invited speaker)  
Robert Wood Johnson Foundation, *Washington, DC*
- 2012 **Large simple clinical trials in insurance systems** (Invited speaker)  
Institute of Medicine of the National Academy of Sciences, *Washington, DC*
- 2012 **Non-adherence and the epidemic of chronic disease** (Grand Rounds)  
Stanford University, Department of Medicine, *Palo Alto, CA*
- 2012 **The impact of full coverage for medications on racial and ethnic disparities in cardiovascular care** (Invited Lecture)  
Aetna Racial and Ethnic Equality External Advisory Committee, *Miami, FL*
- 2013 **The epidemic of chronic disease, medication non-adherence, and the promise of delivery redesign** (Grand Rounds)  
University of Pittsburgh, Department of Medicine, *Pittsburgh, PA*
- 2013 **Current evidence on adherence improvement and expectations for the future** (Invited Lecture)  
3<sup>rd</sup> Patient Adherence and Advocacy Summary, *Philadelphia, PA*
- 2013 **Leveraging value based insurance designs to improve health care quality** (Invited speaker)  
World Congress (webinar)
- 2013 **Engaging consumers and purchasers to improve value** (Invited presentation)  
AcademyHealth, *Washington, DC*
- 2013 **Comparative and cost-effectiveness research** (Invited presentation)  
Howard University, *Washington, DC*

- 2014 **Exploring the use of low-cost randomized experiments to advance evidence-based government** (Invited lecture)  
Coalition for Evidence-Based Policy, *Washington, DC*
- 2014 **Designing low-cost randomized experiments to improve public health** (Invited lecture)  
Center for Disease Control, *Atlanta, Georgia*
- 2014 **Demonstrating how low-cost randomized controlled trials can drive effective social spending** (Invited lecture)  
White House Office of Science and Technology Policy, *Washington, DC*
- 2014 **The benefits, risks and costs of a polypill for cardiovascular risk reduction** (Invited presentation)  
U.S. Food and Drug Administration, *Washington, DC*
- 2014 **The impact of health insurance coverage on racial and ethnic disparities** (Invited presentation)  
U.S. Congressional Health Staff Briefing, *Washington, DC*
- 2015 **Generic drugs are safe and effective. Really?** (Invited lecture)  
Christina Care Health System, *Wilmington, DE*
- 2015 **Low-cost randomized control trials (RCTs): from oxymoron to feasible practice** (Invited lecture)  
Center for Disease Control, *Atlanta, GA*
- 2015 **The epidemic of medication non-adherence and its implications for cardiovascular risk reduction** (Invited lecture)  
Center for Disease Control, *Atlanta, GA*
- 2015 **Pragmatic trials in health insurance systems: designing and evaluating interventions to increase patient engagement** (Keynote lecture)  
University of North Carolina, *Chapel Hill, NC*
- 2015 **Engaging the healthcare system in efforts to enhance adherence** (Plenary lecture)  
University of Pittsburgh, *Pittsburgh, PA*
- 2015 **Evaluating care delivery innovations: the case of medication non-adherence** (Invited lecture)  
Stanford University, Clinical Excellence Research Center, *Palo Alto, CA*
- 2016 **Lost in translation: developing the science of implementation** (Invited lecture)  
Stanford University, Clinical Excellence Research Center, *Palo Alto, CA*
- 2016 **Improving interventions to enhance medication adherence: the role of predictive analytics and other targeting strategies** (Invited lecture)  
University of Pennsylvania, *Philadelphia, PA*

- 2016 **High deductible health plans: state of the science and suggestions for refinement** (Invited lecture)  
AcademyHealth National Health Policy Conference, *Washington, DC*
- 2016 **Using health insurance design to engage patients in making healthy choices** (Invited lecture)  
New England Journal Catalyst Patient Engagement Symposium, *Philadelphia, PA*

Abstract oral presentations

- 1994 **Long-term care policies on life-sustaining treatments** (Conference presentation)  
Canadian Society of Internal Medicine, *Toronto, Canada*
- 1994 **Long-term care facility policies on life-sustaining treatments** (Conference presentation)  
Canadian Geriatrics Society, *Toronto, Canada*
- 1994 **Long-term care centre policies on advance directives** (Conference presentation)  
Canadian Geriatrics Society, *Toronto, Canada*
- 2005 **The impact of adverse-events of warfarin prescribing** (Conference presentation)  
Society of General Internal Medicine Annual Meeting, *New Orleans, LA*
- 2005 **A matched-pair analysis of the impact of adverse events on warfarin prescribing in atrial fibrillation** (Conference presentation)  
AcademyHealth, *Boston, MA*
- 2006 **Should post-MI patients receive secondary prevention medications for free? An economic analysis** (Conference presentation)  
Society of General Internal Medicine Annual Meeting, *Los Angeles, CA*
- 2008 **Setting prices for generic medications** (Conference presentation)  
Society of General Internal Medicine Annual Meeting, *Pittsburgh, PA*
- 2009 **The cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation** (Conference presentation)  
Society of General Internal Medicine Annual Meeting, *Miami, FL*
- 2010 **The implications of therapeutic complexity on medication adherence** (Conference presentation)  
Society of General Internal Medicine Annual Meeting, *Minneapolis, MN*
- 2010 **Reducing copayments for essential cardiovascular medications: evaluation of a natural experiment** (Conference presentation)  
Society of General Internal Medicine Annual Meeting, *Minneapolis, MN*
- 2010 **The implications of therapeutic complexity on adherence to cardiovascular medications** (Conference presentation)  
AcademyHealth, *Boston, MA*

- 2010 **An evaluation of the impact of copayment reductions for essential cardiovascular medications on health spending and clinical outcomes** (Conference presentation)  
AcademyHealth, *Boston, MA*
- 2012 **Untangling the relationship between medication adherence and clinical outcomes: insights from the MI FREEE (Myocardial Infarction Free Rx Event and Economic Evaluation) trial** (Conference presentation)  
AcademyHealth, *Orlando, FL*
- 2013 **Pharmacy-based interventions to reduce primary medication non-adherence** (Conference presentation)  
Society of General Internal Medicine Annual Meeting, *Denver, CO*
- 2013 **The economic consequences of contemporary patterns of antidepressant prescribing** (Conference presentation)  
Society of General Internal Medicine Annual Meeting, *Denver, CO*
- 2013 **The impact of eliminating disparities on disparities in cardiovascular health** (Conference presentation)  
AcademyHealth, *Baltimore, MD*
- 2013 **Financial incentives to improve adherence to evidence-based medications** (Invited lecture)  
AcademyHealth, *Baltimore, MD*

#### International

- 2002 **Fraud, gaming and conflict of interest** (Invited lecture)  
International Association of Medical Licensing Authorities, *Toronto, Canada*
- 2004 **The paradox of clinical experience: implications for quality of care and medical licensure** (Invited lecture)  
University of Toronto Law School Health Law and Policy Seminar Series, *Toronto, Canada*
- 2005 **The impact of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial on prescribing for atrial fibrillation** (Invited lecture)  
Canadian Institutes of Health Research New Emerging Team Workshop on Pharmacologic Management of Chronic Disease in Adult, *Toronto, Canada*
- 2009 **Medication adherence after myocardial infarction: from policy to practice** (Invited lecture)  
University of British Columbia, Centre for Health Services and Policy Research, *Vancouver, Canada*
- 2009 **Reducing the cost of essential medications: how evidence-based policymaking can improve the use of evidence-based medicines** (Grand Rounds)  
University of Ottawa, Ottawa Hospital, *Ottawa, Canada*
- 2009 **The benefits, risks and costs of antiplatelet agents for the prevention of vascular events** (Grand Rounds)  
JSS Medical College, *Mysore, India*

- 2009 **Improving adherence to essential medications** (Grand Rounds)  
JSS Medical College, *Mysore, India*
- 2010 **Could giving away prescription medications for free save Ontario money?: Empirical lessons from south of the border** (Invited lecture)  
Faculty of Law, University of Toronto, *Toronto, Canada*
- 2011 **The cost-effectiveness of pharmacogenetic therapies** (Invited lecture)  
International GenomeHeart Network, *Toronto, Canada*
- 2012 **Methods for conducting benefit-risk analysis** (Invited lecture)  
Asian Conference on Pharmacoepidemiology, *Bangalore, India*
- 2012 **An introduction to comparative effectiveness analysis** (Invited lecture)  
Asian Conference on Pharmacoepidemiology, *Bangalore, India*
- 2012 **Improving adherence to evidence-based medications** (Keynote Speaker)  
University of Saskatchewan, *Saskatchewan, Canada*
- 2013 **The contribution of health system factors to the epidemic of non-adherence** (Invited lecture)  
International Society of Pharmacoepidemiology Annual Meeting, *Montreal, Canada*
- 2014 **Using the healthcare system to our advantage: large simple clinical trials in adherence improvement research** (Keynote Lecture)  
European Society for Patient Adherence, Compliance and Persistence Annual Meeting, *Lausanne, Switzerland*

Abstract oral presentations

- 2005 **Why don't patients with atrial fibrillation receive anticoagulation?** (Conference presentation)  
International Society of Pharmacoepidemiology Annual Meeting, *Nashville, TN*
- 2005 **The impact of adverse events on warfarin prescribing in atrial fibrillation** (Conference presentation)  
International Society of Pharmacoepidemiology Annual Meeting, *Nashville, TN*
- 2006 **An analysis of statin dose and class effects for patients with acute coronary syndromes** (Conference presentation)  
International Society of Pharmacoepidemiology Annual Meeting, *Lisbon, Portugal*
- 2007 **A comparison of the impact of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) trial on prescribing patterns in Canada and the United States** (Conference presentation)  
International Society of Pharmacoepidemiology Annual Meeting, *Quebec, Canada*

- 2008 **Trends in adherence to secondary prevention medications in elderly post-MI patients** (Conference presentation)  
International Society of Pharmacoepidemiology Annual Meeting, *Copenhagen, Denmark*
- 2008 **Setting prices for generic medications: a survey of patient perceptions** (Conference presentation)  
International Society of Pharmacoepidemiology Annual Meeting, *Copenhagen, Denmark*
- 2010 **The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels** (Conference presentation)  
International Society of Pharmacoepidemiology Annual Meeting, *Brighton, United Kingdom*
- 2012 **Comparative cost-effectiveness of interventions to improve adherence after myocardial infarction** (Conference presentation)  
International Society of Pharmacoepidemiology Annual Meeting, *Barcelona, Spain*
- 2013 **Did the Healthcare Effectiveness Data and Information Set (HEDIS) get it right? Evaluating the quality of a quality measure** (Conference presentation)  
International Society of Pharmacoepidemiology Annual Meeting, *Montreal, Canada*

## **REPORT OF CLINICAL ACTIVITIES AND INNOVATIONS**

### **Current Licensure and Certification**

1997	Licentiate	Medical Council of Canada
1999	Diplomate	American Board of Internal Medicine
2000	Fellow	Royal College of Physicians and Surgeons of Canada
2000	License	College of Physicians and Surgeons of Ontario (Independent Practice)
2003	License	Massachusetts Board of Registration in Medicine

### **Practice Activities**

Hospitalist attending	Hospital teaching practice	Brigham and Women's Hospital	12 weeks per year
-----------------------	----------------------------	------------------------------	-------------------

## **REPORT OF SCHOLARSHIP**

### **Peer-Reviewed Publications in Print or Other Media**

#### *Research Investigations*

(NOTE: all publications in this section present new data)

1. **Choudhry NK**, Ma J, Rasooly I, Singer PA. Long-term care facility policies on life-sustaining treatments and advance directives in Canada. *Journal of the American Geriatrics Society* 1994; 42: 1150-3.
2. **Choudhry NK**, Slaughter PM, Sykora K, Naylor CD. Distributional dilemmas in health policy: large benefits for a few, or smaller benefits for many? *Journal of Health Services Research and Policy* 1997; 2: 212-6.
3. Sheth TN, **Choudhry NK**, Bowes M, Detsky AS. The relation of conjunctival pallor to the presence of anemia. *Journal of General Internal Medicine* 1997; 12: 102-6.

4. Etchells E, Katz MR, Shuchman M, Wong G, Workman S, **Choudhry NK**, Craven J, Singer PA. Accuracy of clinical impressions on Mini-Mental State Exam scores for assessing capacity of consent to major medical treatment. *Psychosomatics* 1997; 38: 239-45.
5. **Choudhry NK**, Etchells EE. The rational clinical examination: Does this patient have aortic regurgitation? *Journal of the American Medical Association*. (JAMA) 1999; 281: 2231-8.
6. **Choudhry NK**, Stelfox T, Detsky AS. The relationship between the pharmaceutical industry and authors of clinical practice guidelines. *Journal of the American Medical Association (JAMA)* 2002; 287: 612-7.
7. **Choudhry NK**, Choudhry S, Singer PA. CPR for Patients Labeled DNR: the role of the limited aggressive therapy order. *Annals of Internal Medicine* 2003; 138: 65-8.
8. Suzuki S, Moro-oka T, **Choudhry NK**. Meta-analytic techniques to compare the accuracy of diagnostic tests: a review of the literature and recommendations for a novel methodology. *Journal of Clinical Epidemiology* 2004; 57: 461-9.
9. Choudhry S, **Choudhry NK**, Brown AD. Unregulated private markets for health care in Canada: rules of professional conduct, physician kickbacks, and physician self-referral. *Canadian Medical Association Journal* 2004; 170: 1115-8.
10. **Choudhry NK**, Fletcher RB, Soumerai SB. The paradoxical relationship between clinical experience and various measures of health care quality: a systematic review. *Annals of Internal Medicine* 2005; 142: 260-73.
11. **Choudhry NK**, Singh JM, Barolet A, Tomlinson G, Detsky AS. How should patients with unstable angina and non-ST-elevation acute myocardial infarction be managed?: a meta-analysis of randomized trials. *American Journal of Medicine*; 2005; 118: 465-74.
12. Thavendiranathan P, Bagai A, Ebdia A, Detsky AS, **Choudhry NK**. Do blood tests cause anemia in hospitalized patients? An analysis of the effect of diagnostic phlebotomy on hemoglobin and hematocrit levels. *Journal of General Internal Medicine*; 2005; 20: 520-4.
13. Choudhry S, **Choudhry NK**, Brennan TB. Specialty v. community hospitals: what role for the law? *Health Affairs*; 2005; 0: hlthaff.w5.361v1.
14. Kachalia A, **Choudhry NK**, Studdert D. Emerging physician responses to the malpractice crisis. *Journal of Law, Medicine, and Ethics*; 2005; 33: 416-28.
15. **Choudhry NK**, Anderson G, Laupacis A, Ross-Degnan D, Normand SL, Soumerai SB. The impact of adverse events on warfarin prescribing in atrial fibrillation: a matched-pair analysis. *BMJ* 2006; 332: 141-5.
16. Udell J, Fischer MA, Solomon DH, **Choudhry NK**. Utilization and costs of preventative therapies for osteoporosis: the impact of the Women's Health Initiative: a time-series analysis. *Journal of Bone Mineral Research* 2006; 21: 765-71.
17. **Choudhry NK**, Soumerai SB, Normand S-L, Ross-Degnan D, Laupacis A, Anderson G. Warfarin prescribing in atrial fibrillation: the impact of physician, patient and hospital characteristics. *American Journal of Medicine* 2006; 119: 607-16.
18. Shrank WH, Joseph GJ, **Choudhry NK**, Young HN, Ettner SL, Glassman P, Asch SM, Kravitz RL. Relevant prescription drug costs to physicians: do costs to the individual patient or the population matter most? *American Journal of Managed Care* 2006; 12: 545-51.
19. Thavendiranathan P, Bagai A, Brookhart MA, **Choudhry NK**. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. *Archives of Internal Medicine* 2006; 166: 2307-13.
20. **Choudhry NK**, Avorn J, Antman EA, Schneeweiss S, Shrank WH. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. *Health Affairs* 2007; 26: 186-94.



21. Roy CR, Minor M, Brookhart MA, **Choudhry NK**. The rational clinical examination: Does this patient with a pericardial effusion have cardiac tamponade. *Journal of the American Medical Association* 2007; 297: 1810-1818.
22. Fischer MA, **Choudhry NK**, Winkelmayr WC. Impact of Medicaid prior authorization on angiotensin receptor blockers: can policy promote rational prescribing? *Health Affairs* 2007; 26: 800-7.
23. **Choudhry NK**, Levin R, Winkelmayr WC. Statins in elderly acute coronary syndrome patients: an analysis of dose and class effects in typical practice. *Heart* 2007; 93: 945-51.
24. Shrank WH, Agnew-Blais J, **Choudhry NK**, Wolf MS, Kesselheim A, Avorn J, Shekelle P. The variability and quality of medication container labels. *Archives of Internal Medicine* 2007; 167: 1760-5.
25. Kulik A, Levin R, Ruel M, Mesana TG, Solomon DH, **Choudhry NK**. Patterns and predictors of statin use after coronary artery bypass graft surgery. *Journal of Thoracic Cardiovascular Surgery* 2007; 134: 932-8.
26. Wang PS, Schneeweiss S, Setoguchi S, Patrick A, Avorn J, Mogun H, **Choudhry NK**, Brookhart MA. Ventricular arrhythmias and cerebrovascular events in elderly using conventional and atypical antipsychotic medications. *Journal of Clinical Psychopharmacology* 2007; 27: 707-10.
27. Cadarette SM, Katz JN, Brookhart MA, Levin R, Stedman MR, **Choudhry NK**, Solomon DH. Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004. *Journal of Rheumatology* 2008; 35: 318-26.
28. **Choudhry NK**, Patrick AR, Antman EA, Avorn J, Shrank WH. The cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. *Circulation* 2008; 117 1261-8.
29. Bowry ADK, Brookhart AM, **Choudhry NK**. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. *American Journal of Cardiology* 2008; 101: 960-6.
30. **Choudhry NK**, Levin R, Avorn J. The economic consequences of non-evidence-based clopidogrel use. *American Heart Journal* 2008; 155: 904-9.
31. **Choudhry NK**, Brennan T, Toscano M, Spettell C, Glynn RJ, Rubino M, Schneeweiss S, Brookhart MA, Fernandes J, Mathew S, Christiansen B, Antman EM, Avorn A, Shrank WH. Rationale and Design of The Post-Myocardial Infarction Free Rx Event and Economic Evaluation (POST-MI FREEE) Trial: a randomized evaluation of first-dollar drug coverage for post-MI secondary preventive therapies. *American Heart Journal* 2008; 156: 31-6.
32. Block EA, Solomon DH, Cadarette SM, Mogun H, **Choudhry NK**. Patient and physician predictors of post-fracture osteoporosis management. *Journal of General Internal Medicine* 2008; 23: 1447-51.
33. Upadhyay G, **Choudhry NK**, Auricchio A, Ruskin J, Singh JP. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. *Journal of the American College of Cardiology* 2008; 52: 1239-46.
34. Kulik A, Brookhart MA, Levin R, Ruel M, Solomon DH, **Choudhry NK**. Impact of statin use on outcomes after coronary artery bypass graft surgery. *Circulation* 2008; 118: 1785-92.
35. **Choudhry NK**, Zagorski B, Avorn J, Levin R, Sykora K, Laupacis A, Mamdani M. Comparison of the impact of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial on prescribing patterns: a time-series analysis. *Annals of Pharmacotherapy* 2008; 42: 1563-72.
36. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, **Choudhry NK**, Shrank WH. The clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. *JAMA* 2008; 300: 2514-26.
37. **Choudhry NK**, Setoguchi S, Levin R, Winkelmayr WC, Shrank WH. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. *Pharmacoepidemiology and Drug Safety* 2008; 17: 1189-96.

38. Wolf MS, Shekelle P, **Choudhry NK**, Agnew-Blais J, Parker RM, Shrank WH. Variability in pharmacy interpretations of physician prescriptions. *Medical Care* 2009; 47: 370-3.
39. Shrank WH, Cox E, Fischer MA, Mehta J, **Choudhry NK**. Patient perceptions of generic medications. *Health Affairs* 2009; 28: 546-56.
40. Gellad WF, **Choudhry NK**, Friedberg MW, Brookhart AM, Haas JS, Shrank WH. Variation in drug prices at pharmacies: do the poor pay more? *Health Services Research* 2009; 44: 606-17.
41. Shrank WH, **Choudhry NK**, Solomon DH, Snedden TM, Lee TH, Glynn RJ, Brown TV, Jolda C, Spetman M, Brookhart MA, Schneeweiss S, Avorn J. Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. *American Heart Journal* 2009; 157: 613-9.
42. Shrank WH, Gleason PP, Canning C, Walters C, Heaton AH, Jan S, Patrick A, Brookhart MA, Schneeweiss S, Solomon DH, Avorn J, **Choudhry NK**. Can improved prescription medication labeling influence adherence to chronic medications? An evaluation of the Target Pharmacy label. *Journal of General Internal Medicine* 2009; 24: 570-8.
43. **Choudhry NK**, Lee JL, Agnew-Blais J, Corcoran CP, Shrank WH. Drug company-sponsored patient assistance programs: a viable safety net? *Health Affairs* 2009; 28: 827-34.
44. Charytan DM, Wallentin L, Lagerqvist B, Spacek R, De Winter RJ, Stern NM, Braunwald E, Cannon CP, **Choudhry NK**. Early angiography in patients with chronic kidney disease: a collaborative systematic review. *Clinical Journal of the American Association of Nephrology* 2009; 4:1032-43.
45. **Choudhry NK**, Shrank WH, Levin R, Lee LJ, Jan S, Brookhart MA, Solomon DH. Measuring concurrent adherence to multiple related medications. *American Journal of Managed Care* 2009; 15: 457-64.
46. Patrick AR, Avorn J, **Choudhry NK**. The cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. *Circulation: Cardiovascular Quality and Outcomes* 2009; 2: 429-36.
47. Shrank WH, Patrick AR, Gleason PP, Canning C, Walters C, Heaton AH, Jan S, Brookhart MA, Schneeweiss S, Solomon DH, Wolf MS, Avorn J, **Choudhry NK**. An evaluation of the relationship between the implementation of a newly designed prescription drug label at Target Pharmacies and health outcomes. *Medical Care* 2009; 47: 1031-5.
48. Solomon DH, Cadarette SM, **Choudhry NK**, Canning C, Levin R, Stürmer T. A cohort study of thiazolidinediones and fractures in older adults with diabetes. *Journal of Clinical Endocrinology and Metabolism* 2009; 94: 2792-8.
49. Shrank WH, Cadarette SM, Cox E, Fischer MA, Mehta J, Brookhart MA, Avorn J, **Choudhry NK**. Is there a relationship between patient beliefs or communication about generic drugs and medication utilization? *Medical Care* 2009; 47: 319-25.
50. Thavendiranathan P, Bagai A, Khoo C, Dorian P, **Choudhry NK**. Does this patient with palpitations have a cardiac arrhythmia? *Journal of the American Medical Association* 2009; 302: 2135-2143.
51. Rassen JA, **Choudhry NK**, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. *Circulation* 2009; 120: 2322-9.
52. Dhalla IA, Smith MA, **Choudhry NK**, Denburg AE. Costs and benefits of free medications after myocardial infarction. *Healthcare Policy* 2009; 5: 69-86.
53. **Choudhry NK**, Cox E, Fischer MA, Mehta J, Shrank WH. Setting prices for generic medications: a survey of patient perceptions. *American Journal of Pharmacy Benefits* 2010; 2: 33-8.
54. Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J, Avorn J, Solomon DH, Brookhart MA, **Choudhry NK**. Patient, physician, and payment determinants of statin adherence. *Medical Care* 2010; 48: 196–202.
55. Kulik A, Singh JP, Levin R, Avorn J, **Choudhry NK**. Association between statin use and the incidence of atrial fibrillation following hospitalization for coronary artery disease. *American Journal of Cardiology* 2010; 105: 1655-1660.

56. Shrank WH, **Choudhry NK**, Agnew-Blais J, Federman AD, Liberman JN, Liu J, Kesselheim AS, Brookhart MA, Fischer MA. The effect of state law variation on generic simvastatin use after patent expiration. *Health Affairs* 2010; 29: 1383-1390.
57. Cutrona SL, **Choudhry NK**, Stedman M, Servi A, Liberman JN, Brennan T, Fischer MA, Brookhart MA, Shrank WH. Physician effectiveness in interventions to improve cardiovascular medication adherence: A systematic review. *Journal of General Internal Medicine* 2010; 25: 1090-1096.
58. Setoguchi S, **Choudhry NK**, Levin R, Shrank WH, Winkelmayer WC. Temporal trends in adherence to cardiovascular medications after heart failure hospitalization in the elderly. *Clinical Pharmacology and Therapeutics* 2010; 88: 548-54.
59. **Choudhry NK**, Fischer MA, Avorn J, Schneeweiss S, Solomon DH, Berman C, Jan S, Liu J, Lii J, Brookhart AM, Mahoney J, Shrank WH. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. *Health Affairs* 2010; 29: 1995-2001.
60. **Choudhry NK**, Rosenthal MB, Milstein A. Assessing the evidence for value-based insurance design. *Health Affairs* 2010; 29: 1988-1994.
61. Shrank WH, **Choudhry NK**, Fischer MA, Avorn J, Powell M, Schneeweiss S, Liberman JN, Dollear T, Brennan TA, Brookhart MA. The epidemiology of prescriptions abandoned at the pharmacy. *Annals of Internal Medicine* 2010; 153: 633-640.
62. Parikh S, Shrank WH, Mogun H, **Choudhry NK**. Statin utilization in nursing home patients after cardiac hospitalization. *Journal of General Internal Medicine* 2010; 25: 1293-1299.
63. Cutrona SL, **Choudhry NK**, Fischer MA, Servi A, Liberman JN, Brennan TA, Shrank WH. Modes of delivery for interventions to improve cardiovascular medication adherence: A systematic review. *American Journal of Managed Care* 2010; 16: 929-942.
64. Misono AS, Cutrona SL, **Choudhry NK**, Stedman M, Fischer MA, Liberman JN, Brennan T, Jain SH, Shrank WH. Effectiveness of healthcare information technology (HIT) adherence interventions in cardiovascular disease and diabetes: a systematic review. *American Journal of Managed Care*; 2010; 16(12 Spec No.): SP82-SP92.
65. Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, **Choudhry NK**. Physician perceptions about generic drugs. *Annals of Pharmacotherapy* 2011; 45:31-8.
66. Greene JA, **Choudhry NK**, Kilabuk E, Shrank WH. Online social networking by patients with diabetes: A qualitative evaluation of communication with Facebook. *Journal of General Internal Medicine* 2011; 26: 287-92.
67. **Choudhry NK**, Fischer MA, Avorn J, Liberman, LN, Schneeweiss S, Pakes, J, Brennan TA, Shrank WH. The implications of therapeutic complexity on adherence to cardiovascular medications. *Archives of Internal Medicine* 2011; 171: 814-822.
68. **Choudhry NK**, Patrick AR, Glynn RJ, Avorn J. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. *Journal of the American College of Cardiology* 2011; 57: 784-91.
69. Shrank WH, Liberman JN, Fischer MA, Avorn J, Kilabuk E, Chang A, Kesselheim AS, Brennan TA, **Choudhry NK**. The consequences of requesting "Dispense as Written". *American Journal of Medicine* 2011; 124: 309-17.
70. Kulik A, Shrank WH, Levin R, **Choudhry NK**. Adherence to statin therapy in elderly patients after hospitalization for coronary revascularization. *American Journal of Cardiology* 2011; 107: 1409-1414.
71. Shrank WH, **Choudhry NK**, Brennan TB. Analysis suggests that the use of generic drugs in prevention of chronic disease is far more cost effective than thought, and may potentially save money. *Health Affairs* 2011; 30: 1351-1357.
72. Shrank WH, Liberman JN, Fischer MA, Kilabuk E, Girdish C, Cutrona SL, Brennan T, **Choudhry NK**. Are caregivers adherent to their own medications? *Journal of the American Pharmacists Association* 2011; 51: 492-8.

73. Hayward RM, Upadhyay GA, Mela T, Ellinor PT, Barrett C, Heist K, Verma A, **Choudhry NK**, Singh JP. Pulmonary vein isolation with complex fractionated atrial electrogram ablation for paroxysmal and nonparoxysmal atrial fibrillation: a meta-analysis. *Heart Rhythm* 2011; 994-1000.
74. Margulis AV, **Choudhry NK**, Dormuth CR, Schneeweiss S. Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004. *Pharmacoepidemiology and Drug Safety* 2011; 20:1088-97.
75. Winkelmayr WC, Liu J, Setoguchi S, **Choudhry NK**. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. *Clinical Journal of the American Society of Nephrology* 2011; 6: 2662-68.
76. Shrank WH, **Choudhry NK**, Swanton K, Jain S, Greene MD JA, Harlam B, Patel KP. Variations in structure and content of online social networks for diabetics. *Archives of Internal Medicine* 2011; 171:1589-91.
77. Bowry ADK, Shrank WH, Lee JL, Stedman M, **Choudhry NK**. A systematic review of adherence to cardiovascular medications in resource-limited settings. *Journal of General Internal Medicine* 2011; 26: 1479-91.
78. Fischer MA, **Choudhry NK**, Brill G, et al. Trouble getting started: predictors of primary medication nonadherence. *American Journal of Medicine* 2011; 124: 1081 e9-e22.
79. **Choudhry NK**, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, Reisman L, Fernandes J, Spettell C, Lee JL, Levin R, Brennan T, Shrank WH. Full coverage for preventive medications after myocardial infarction. *New England Journal of Medicine* 2011; 365: 2088-2097.
80. Brennan T, Dollear T, Hu M, Matlin OS, Shrank WH, **Choudhry NK**, Grambley W. An integrated pharmacy-based program improved medication prescription and adherence rates in diabetes patients. *Health Affairs* 2012; 31: 120-129.
81. Desai NR, Shrank WH, Fischer MA, Avorn, J, Liberman JN, Schneeweiss S, Pakes J, Brennan TA, **Choudhry NK**. Patterns of medication initiation in newly diagnosed diabetes mellitus – quality and cost implications. *American Journal of Medicine* 2012: 125: 302e1-302e7.
82. **Choudhry NK**, Saya UY, Shrank WH, Greenberg JO, Melia C, Bilodeau A, Kadehjian EK, Dolan ML, Dudley JC, Kachalia A. Cost-related medication underuse: prevalence among hospitalized managed care patients. *Journal of Hospital Medicine* 2012; 7: 104-109.
83. Kesselheim AS, Lee JL, Avorn J, Servi A, Shrank WH, **Choudhry NK**. Conflict of interest in oncology publications: a survey of disclosure policies and statements. *Cancer* 2012; 118: 188-195.
84. Chatterjee NA, Upadhyay GA, Ellenbogen KA, McAlister FA, **Choudhry NK**, Singh JP. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review. *Circulation: Arrhythmia and Electrophysiology*; 2012; 5: 68-76.
85. Cutrona SL, **Choudhry NK**, Fischer MA, Servi A, Stedman M, Liberman JN, Shrank WH. Targeting cardiovascular medication adherence interventions: a systematic review. *Journal of the American Pharmacists Association* 2012; 52: 381-397.
86. Winkelmayr WC, Liu J, Patrick AR, Setoguchi S, **Choudhry NK**. Prevalence of atrial fibrillation and warfarin treatment in older patients receiving hemodialysis. *Journal of Nephrology* 2012; 25:341-53.
87. Shrank WH, **Choudhry NK**, Tong A, Myers J, Fishcer MA, Swanton K, Slezak J, Brennan TA, Liberman JN, Roebuck C, Moffit S, Avorn J, Carpenter D. Warnings without Guidance: Patient responses to an FDA warning about Ezetimibe. *Medical Care* 2012; 50:479-84
88. Schneeweiss S, Gagne JJ, Patrick AR, **Choudhry NK**, Avorn J. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. *Circulation: Cardiovasc Qual Outcomes* 2012; 5: 480-486.
89. Wang B, Gagne JJ, **Choudhry NK**. The epidemiology of drug recalls in the US. *Archives of Internal Medicine* 2012; 172: 1110-1.

90. Greene JA, **Choudhry NK**, Kesselheim AS, Brennan TA, Shrank WH. Changes in direct-to-consumer pharmaceutical advertising following shifts from prescription-only to over-the-counter status. *JAMA: The Journal of the American Medical Association* 2012; 308: 973-5.
91. Singh JP, Kulik A, Levin R, Ellnot PT, Ruskin J, Avorn J, **Choudhry NK**. Renin-angiotensin-system modulators and the incidence of atrial fibrillation following hospitalization for coronary artery disease. *Europace* 2012; 14: 1287-93.
92. Kulik A, Rassen JA, Myers J, Schneeweiss S, Gagne J, Polinski JM, Liu J, Fischer MA, **Choudhry NK**. Comparative effectiveness of preventative therapy for venous thromboembolism after coronary artery bypass graft surgery. *Circulation: Cardiovascular Interventions* 2012; 5: 590-96.
93. **Choudhry NK**, Fischer MA, Avorn J, Lee JL, Schneeweiss S, Solomon DH, Berman C, Jan S, Lii J, Mahoney JJ, Shrank WH. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. *Journal of the American College of Cardiology* 2012; 60: 1817-24.
94. Ito K, Shrank WH, Avorn J, Patrick AR, Brennan TA, Antman EM, **Choudhry NK**. Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction. *Health Services Research* 2012; 47: 2097–2117.
95. Canestaro WJ, Brooks DG, Chaplin D, **Choudhry NK**, Lawler E, Martell L, Brennan T, Wassman ER. Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing. *Journal of Personalized Medicine* 2012; 2(4):158-174.
96. Brunelli SM, Waikar SS, Bateman BT, Chang TI, Lii J, Garg AX, Winkelmayr WC, **Choudhry NK**. Pre-operative statin use and post-operative acute kidney injury. *American Journal of Medicine* 2012; 125:1195-204 e3.
97. Lee, JL, Fischer MA, Shrank WH, Polinski JM, **Choudhry NK**. A systematic review of reference pricing: Implications for U.S. prescription spending. *American Journal of Managed Care* 2012; 18: e429-e37.
98. Scheurer DS, **Choudhry NK**, Swanton K, Matlin O, Shrank WH. Association between different types of social support and medication adherence. *American Journal of Managed Care* 2012; 18: e461-e467.
99. Polinski JM, Curtis BH, Seeger JD, **Choudhry NK**, Zagar A, Shrank WH. Rationale and design of the Multinational Observational Study Assessing Insulin use: the MOSAIC study. *BMC Endocrine Diseases* 2012; 12:20. DOI: 10.1186/1472-6823-12-20
100. Polinski JM, Smith BF, Curtis BH, Seeger JD, **Choudhry NK**, Connolly JG, Shrank WH. Barriers to insulin progression among patients with type 2 diabetes: a systematic review. *Diabetes Educ* 2013; 39: 55-67.
101. Kesselheim AS, Misono AS, Shrank WH, Greene JA, Doherty M, Avorn J, **Choudhry NK**. Variations in pill appearance of antiepileptic drugs and the risk of non-adherence. *JAMA Internal Medicine*: 2013; 173: 202-8.
102. Bitton A, **Choudhry NK**, Matlin OS, Swanton K, Shrank WH. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. *American Journal of Medicine* 2013; 126: 357.e357-357.e327.
103. Sussman A, Dunham L, Snower K, Hu M, Matlin AS, Shrank WH, **Choudhry NK**, Brennan TB. Retail clinic utilization associated with lower total cost of care. *American Journal of Managed Care* 2013; 14: e148-157.
104. Lewey J, Shrank WH, Bowry ADK, Kilabuk E, Brennan TA, **Choudhry NK**. Gender and racial disparities in adherence to statin therapy: a meta-analysis. *American Heart Journal* 2013;165:665-678.
105. Lee JL, Maciejewski ML, Shveta R, Shrank WH, **Choudhry NK**. Value-based insurance design: quality improvement but not cost-savings. *Health Affairs* 2013; 32: 1251-1257.
106. Bateman BT, Rassen JA, Schneeweiss S, Bykov K, Myers J, Gagne JJ, Polinski JM, Liu J, Kulik A, Fischer MA, **Choudhry NK**. Adjuvant vancomycin for antibiotic prophylaxis and the risk of

- Clostridium Difficile* after coronary artery bypass graft surgery. *Journal of Thoracic and Cardiovascular Surgery* 2013; 146: 472-8.
107. **Choudhry NK**, Shrank WH. Implementing randomized effectiveness trials in large insurance systems. *Journal of Clinical Epidemiology* 2013; 66(8 Suppl): S5-S11.
  108. Franklin JM, Shrank WH, Pakes J, Sanf elix-Gimeno G, Matlin OS, Brennan TA, **Choudhry NK**. Group-based trajectory models: A new approach to classifying and predicting long-term medication adherence. *Medical Care* 2013; 51: 789-96.
  109. Kulik A, Desai NR, Shrank WH, Antman EM, Glynn RJ, Levin R, Reisman L, Brennan TA, **Choudhry NK**. Full prescription coverage versus usual prescription coverage after coronary artery bypass graft surgery: analysis from the MI FREEE randomized trial. *Circulation* 2013; 128: S219-S225.
  110. Gagne JJ, Bykov K, **Choudhry NK**, Toomey TJ, Connolly JG, Avorn J. Effect of smoking on the comparative efficacy of antiplatelet agents: a systematic review, meta-analysis, and indirect comparison. *BMJ* 2013; 347:f5307 doi: 10.1136/bmj.f5307.
  111. Ito K, Elkin EB, Blinder VS, Keating KL, **Choudhry NK**. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer. *Cancer* 2013; 119:2494-2502.
  112. Gagne JJ, Polinski JM, sheim AS, **Choudhry NK**, Hutchins D, Matlin OS, Tong A, Shrank WH. Patterns and predictors of generic narrow therapeutic index drug use among older adults. *Journal of the American Geriatrics Society*; 2013; 61:1586-1591.
  113. Bateman BT, Bykov K, **Choudhry NK**, Schneeweiss S, Gagne JJ, Polinski JM, Franklin JM, Doherty M, Fischer MA, Rassen JA. Type of stress ulcer prophylaxis and the risk of nosocomial pneumonia in cardiac surgical patients: a cohort study. *BMJ* 2013; 347:f5416.
  114. Desai NR, Canestaro WJ, Kyrychenko P, Chapin D, Martell LA, Brennan T, Matlin OS, **Choudhry NK**. The impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy following acute coronary syndromes and percutaneous coronary intervention. *Circulation: Cardiovascular Quality and Outcomes* 2013; 6: 694-9.
  115. Canestaro WJ, Patrick AR, Avorn J, Ito K, Matlin OS, Brennan TA, Shrank WH, **Choudhry NK**. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. *Circulation: Cardiovascular Quality and Outcomes* 2013; 6: 724-31.
  116. **Choudhry NK**, Glynn RJ, Avorn J, Lee JL, Brennan TA, Reisman L, Toscano M, Levin R, Matlin OS, Antman EM, Shrank WH. Untangling the relationship between medication adherence and post-myocardial infarction outcomes. *American Heart Journal* 2014; 167: 51-58.
  117. Block JP, **Choudhry NK**, Carpenter DP, Fischer MA, Brennan TA, Tong AY, Matlin OS, Shrank WH. Time series analyses of the effect of FDA communications on use of prescription weight loss medications. *Obesity* 2014; 22: 943-949.
  118. Patrick AR, Fischer, MA, **Choudhry NK**, Shrank WH, Seeger JD, Liu J, Avorn J, Polinski JM. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. *Journal of General Internal Medicine* 2014; 29: 320-327.
  119. **Choudhry NK**, Dugani SB, Shrank WH, Polinski JM, Stark C, Gupta R, Prabhakaran D, Brill G, Jha P. Despite increased use and sales of statins in India, per capita prescription rates remain far below high-income countries. *Health Affairs* 2014; 33: 2273-282.
  120. **Choudhry NK**, Fischer MA, Smith BF, Brill G, Girdish C, Matlin OS, Brennan T, Avorn JL, Shrank WH. Five features of value-based insurance design plans were associated with higher rates of medication adherence. *Health Affairs* 2014; 33: 493-501.
  121. Gagne JJ, Rassen JA, **Choudhry NK**, Bohn RL, Patrick AR, Sridhar G, Daniel GW, Liu J, Schneeweiss S. Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. *Drug Safety* 2014; 37: 151-161.
  122. Berkowitz SA, Seligman HK, **Choudhry NK**. Treat or Eat: Food insecurity, cost-related medication underuse and unmet needs. *American Journal of Medicine* 2014; 127: 303-310.

123. Lieberman DA, Polinski JM, **Choudhry NK**, Avorn J, Fischer MA. Unintended consequences of a Medicaid prescription copayment policy. *Medical Care* 2014; 52: 422-427.
124. **Choudhry NK**, Bykov K, Shrank WH, Toscano M, Rawlins W, Reisman L, Brennan T, Franklin JM. Eliminating medication copayments reduces disparities in cardiovascular care. *Health Affairs* 2014; 33: 863-870.
125. Franklin JM, **Choudhry NK**, Uscher-Pines L, Brill G, Matlin OS, Fischer MA, Schneeweiss S, Avorn J, Brennan TA, Shrank WH. Equity in the receipt of oseltamivir during the H1N1 pandemic. *American Journal of Public Health* 2014; 104: 1052-1058.
126. Sanfelix-Gimeno G, Franklin JM, Shrank WH, Carlo M, Tong AY, Reisman L, Matlin OS, Brennan TA, **Choudhry NK**. Did HEDIS get it right? Evaluating the quality of a quality measure: adherence to beta-blockers and cardiovascular outcomes after myocardial infarction. *Medical Care* 2014; 52: 669-76.
127. Moss AC, Lillis Y, George J, **Choudhry NK**, Berg A, Cheifetz AS, Horowitz G, Leffler D. Attitudes to Mesalamine (AtoM) Questionnaire: a novel tool to predict mesalamine non-adherence in patients with IBD. *American Journal Gastroenterology* 2014; 109: 1850-1855.
128. Kesselheim AS, Bykov K, Avorn J, Tong A, Doherty M, **Choudhry NK**. Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. *Annals of Internal Medicine* 2014; 161: 96-103.
129. Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ, Spettell CM, Brennan TA, Matlin OS, Avorn J, **Choudhry NK**. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation – quality and cost implications. *American Journal of Medicine* 2014; 127: 1075-1082
130. Gagne JJ, **Choudhry NK**, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, Brennan TA, Avorn J, Shrank WH. Comparative effectiveness of generic and brand-name statins on patient outcomes. *Annals of Internal Medicine* 2014; 400-407.
131. Wang B, Canestaro WJ, **Choudhry NK**. Clinical evidence supporting pharmacogenomic testing provided in FDA drug labels. *JAMA Internal Medicine* 2014; 174: 1938-1944.
132. Krumme AA, **Choudhry NK**, Shrank WH, Brennan TA, Matlin OS, Brill G, Gagne JJ. Cigarette purchases at pharmacies by patients at high risk of smoking-related illness. *JAMA Internal Medicine* 2014; 174:2031-2032.
133. Berkowitz SA, Krumme AA, Avorn J, Brennan TA, Matlin OS, Spettell CM, Pezalla E, Brill G, Shrank WH, **Choudhry NK**. Initial choice of oral glucose-lowering medication for diabetes: a patient-centered comparative effectiveness study. *JAMA Internal Medicine* 2014; 174:1955-1962.
134. Fischer MA, **Choudhry NK**, Bykov K, Brill G, Bopp G, Wurst AM, Shrank WH. Pharmacy-based interventions to reduce primary medication non-adherence to cardiovascular medications. *Medical Care* 2014; 52:1050-4.
135. Shrank WH, Krumme AA, Tong AY, Spettell CM, Matlin O, Sussman A, Brennan TA, **Choudhry NK**. Quality of Care Delivered at Retail Clinics for Three Common Conditions. *American Journal of Managed Care* 2014; 20: 794-801.
136. Najafzadeh M, Gagne JJ, **Choudhry NK**, Polinski J, Avorn J, Schneeweiss S. Patients' preferences in anticoagulant therapy: discrete choice experiment. *Circulation: Cardiovascular Quality and Outcomes* 2014; 7: 912-9.
137. Polinski JM, Kesselheim AS, Seeger JD, Connolly JG, **Choudhry NK**, Shrank WH. A cross-national comparison of 17 countries' insulin glargine drug labels. *Pharmacoepidemiology and Drug Safety*; 2015; 24:159-65.
138. Kesselheim AS, Huybrechts KF, **Choudhry NK**, Fulchino LA, Isaman DL, Kowal MK, Brennan TA. Prescription drug insurance coverage and patient health outcomes: A systematic review. *American Journal of Public Health* 2015; 105: e17-30.

139. Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, **Choudhry NK**. Cost-effectiveness of novel regimens for the treatment of hepatitis C. *Annals of Internal Medicine* 2015; 162: 407-419.
140. Sarpatwari A, **Choudhry NK**, Avorn J, Kesselheim AS. Paying physicians to prescribe generic drug and follow-on biologics in the United States. *PLoS Medicine* 2015; 12: e1001802.
141. Wang B, **Choudhry NK**, Gagne JJ, Landon J, Kesselheim AS. Availability and utilization of cardiovascular fixed-dose combination drugs in the United States. *American Heart Journal* 2015; 169: 379-386
142. Gagne JJ, Polinski JM, Rassen JA, Fischer MA, Seeger JD, Franklin JM, Liu J, Schneeweiss S, **Choudhry NK**. Selective serotonin reuptake inhibitor use and perioperative bleeding and mortality in patients undergoing coronary artery bypass grafting: a cohort study. *Drug Safety* 2015; 38: 1075-82.
143. Najafzadeh M, Schneeweiss S, **Choudhry NK**, Bykov K, Kahler KH, Martin DP, Gagne JJ. A unified framework for classification of methods for benefit-risk assessment. *Value in Health* 2015; 18:250-259.
144. Ito K, Avorn J, Shrank WH, Toscano M, Spetell C, Brennan T, **Choudhry NK**. Long-term cost-effectiveness of providing full coverage for preventive medications after myocardial infarction. *Circulation: Cardiovascular Quality and Outcomes* 2015; 8: 252-259.
145. Lewey J, Shrank WH, Avorn J, Liu J, **Choudhry NK**. Medication adherence and healthcare disparities: impact of statin copayment reduction. *American Journal of Managed Care* 2015; 21: 696-704.
146. Franklin JM, Krumme AK, Tong AY, Shrank WH, Matlin OS, Brennan TA, **Choudhry NK**. Association between trajectories of statin adherence and subsequent cardiovascular events. *Pharmacoepidemiology and Drug Safety*; 2015; 24: 1105-13.
147. Kulik A, Bykov K, **Choudhry NK**, Bateman BT. Non-steroidal anti-inflammatory drug administration after coronary artery bypass surgery: utilization persists despite the boxed warning. *Pharmacoepidemiology and Drug Safety* 2015; 24: 647-653
148. Franklin JM, Krumme AA, Shrank WH, Matlin OS, Brennan TA, **Choudhry NK**. Predicting adherence trajectory using initial patterns of medication filling. *American Journal of Managed Care* 2015; 21: 294-301.
149. **Choudhry NK**, Krumme AA, Ercole PM, Girdish C, Isaman DL, Matlin OS, Brennan TA, Shrank WH, Franklin JM. Rationale and design of the randomized evaluation to measure improvements in non-adherence from low-cost devices (REMIND) trial. *Contemporary Clinical Trials* 2015; 43: 53-59.
150. Bykov K, Franklin JM, Toscano M, Rawlins W, McMahill-Walraven CN, Spetell CM, Shrank WH, **Choudhry NK**. Evaluating cardiovascular health disparities using estimated race/ethnicity: a validation study. *Medical Care* 2015; 53: 1050–1057.
151. Kim SC, Schneeweiss S, **Choudhry NK**, Liu J, Glynn RJ, Solomon DH. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: A cohort study. *American Journal of Medicine* 2015; 128: 653 e657-653.
152. Matlin OS, Kymes SM, Averbukh A, **Choudhry NK**, Brennan TA, Bunton A, Ducharme TA, Simmons PD, Shrank WH. Community pharmacy automatic refill program improves adherence to maintenance therapy and reduces wasted medication. *American Journal of Managed Care*; 2015; 21: 785-91.
153. Gagne JJ, Najafzadeh M, **Choudhry NK**, Bykov K, Kahler KH, Martin D, Rogers JR, Schneeweiss S. Comparison of benefit-risk assessment methods for prospective monitoring of newly marketed drugs: a simulation study. *Value in Health* 2015; 8: 1057-1062.
154. Gagne JJ, Bykov K, Najafzadeh M, **Choudhry NK**, Martin D, Kahler KH, Rogers JR, Schneeweiss S. Prospective benefit-risk monitoring of new drugs for rapid assessment of net favorability in electronic healthcare data. *Value in Health* 2015; 8: 1063-1069.



155. Gagne JJ, Kesselheim AS, **Choudhry NK**, Polinski JM, Hutchins D, Matlin OS, Brennan TA, Avorn J, Shrank WH. Comparative effectiveness of generic versus brand-name antiepileptic medications. *Epilepsy & Behavior* 2015; 52(Pt A):14-8.
156. Lieberman DA, Polinski JM, **Choudhry NK**, Avorn J, Fischer MA. Medicaid prescription limits: policy trends and comparative impact on utilization. *BMC Health Services Research*. 2016; 16(1): 15.
157. Lee JL, **Choudhry NK**, Wu AW, Matlin O, Brennan TA, Shrank WH. Patient use of email, Facebook, and physician websites to communicate with healthcare providers. *Journal of General Internal Medicine*; 2016; 31: 45-51.
158. Franklin JM, Shrank WH, Lii J, Krumme AK, Matlin OS, Brennan TA, **Choudhry NK**. Observing versus Predicting: Initial Patterns of Filling Predict Long-Term Adherence More Accurately Than High-Dimensional Modeling Techniques. *Health Services Research*. 2016; 51: 220-39.
159. Krumme AA, Isaman DL, Stolpe SF, Dougherty JS, **Choudhry NK**. Prevalence, effectiveness, and characteristics of pharmacy-based medication synchronization programs. *American Journal of Managed Care*. 2016; 22(3): 179-186.

160.

(b) (4)

161.

162.

163.

#### Other Peer-Reviewed Publications

1. **Choudhry NK**, Wright JG, Singer PA. Outcome rates for individual surgeons: concerns about accuracy, completeness and consequences of disclosure. *Surgery* 1994; 115: 406-8.
2. **Choudhry NK**, Naylor CD. Reflections on supply-demand mismatch in dialysis services in Ontario. *Canadian Medical Association Journal* 1995; 153: 575-81.
3. **Choudhry NK**, Detsky AS. A perspective on U.S. drug re-importation. *Journal of the American Medical Association (JAMA)* 2005; 293: 358-61.
4. **Choudhry NK**, Avorn J. Over-the-counter statins. *Annals of Internal Medicine*; 2005; 142: 910-3.
5. Kesselheim AS, **Choudhry NK**. The international pharmaceutical market as a source of low-cost prescription drugs for U.S. patients. *Annals of Internal Medicine*; 2008; 148: 614-9.
6. Gellad WF, Detsky AS, **Choudhry NK**. The implications of recent clinical trials on pay-for-performance. *American Journal of Health-System Pharmacy* 2009; 66: 864-7.
7. Shrank WH, Porter ME, Jain S, **Choudhry NK**. A blueprint for pharmacy benefits managers to increase value. *American Journal of Managed Care* 2009; 15: 87-93.
8. Avorn J, **Choudhry NK**. Funding for medical education: maintaining a healthy separation from industry. *Circulation* 2010; 121: 2228-34.
9. Desai NR, **Choudhry NK**. Impediments to adherence with post myocardial infarction medications. *Current Cardiology Reports* 2013; 15: 322.
10. Lewey J, **Choudhry NK**. The current state of ethnic and racial disparities in cardiovascular care: lessons from the past and opportunities for the future. *Current Cardiology Reports* 2014;16: 530.

11. Bowry, ADK, Lewey, J, Dugani, SD, **Choudhry, NK**. Epidemiology of cardiovascular disease in low and middle income countries. *Canadian Journal of Cardiology* 2015; 31:1151-1159.
12. **Choudhry NK**, Denberg TD, Qaseem A. Improved adherence to therapy and clinical outcomes while containing costs: opportunities from the greater use of generic medications: Best Practice Advice from the Clinical Guidelines Committee of the American College of Physicians; *Annals of Internal Medicine* 2016; 164: 41-9.
13. (b) (4)

## Non-Peer Reviewed Publications

### Editorials

1. Avorn J, **Choudhry NK**. Using computer-based decision support to close the “know-do” gap in lipid-lowering therapy. *Circulation* 2008; 117:336-7.
2. **Choudhry NK**, Winkelmayer WC. Medication adherence after myocardial infarction: a long way left to go. *Journal of General Internal Medicine* 2008; 23: 216-8.
3. **Choudhry NK**. Co-payment levels and medication adherence: less is more. *Circulation* 2009; 119: 365-7.
4. **Choudhry NK**, Lee JL, Agnew-Blais J, Corcoran CP, Shrank WH. Patient assistance programs: information is not our enemy. *Health Affairs* 2009; 28: 843-4.
5. **Choudhry NK**. The relationship between high drug cost-sharing and adverse clinical outcomes: a truism that’s tough to prove. *American Journal of Managed Care* 2010; 16: 287-9.
6. **Choudhry NK**. Improving the pathway from cardiovascular medication prescribing to longer-term adherence: new results about old issues. *Circulation: Cardiovascular Quality and Outcomes*; 2010; 3; 223-225.
7. Shrank WH, **Choudhry NK**. Comparative effectiveness research: is “synchronicity” a valid outcome? *American Journal of Pharmacy Benefits* 2010; 2: 195-196.
8. **Choudhry NK**, Shrank WH. Four-dollar generics - increased accessibility, impaired quality assurance. *New England Journal of Medicine* 2010; 363: 1885-1887.
9. Shrank WH, **Choudhry NK**. Time to fill the doughnuts: health care reform and Medicare Part D. *New England Journal of Medicine* 2011; 364: 598-601.
10. Gagne JJ, **Choudhry NK**. How many me-too’s is too many? *Journal of the American Medical Association* 2011; 305: 711-712.
11. **Choudhry NK**. Promoting persistence: improving adherence through choice of drug class. *Circulation* 2011; 123: 1584-6.
12. Shrank WH, **Choudhry NK**. Affect and affirmation—basic approaches to promote adherence. *Nature Reviews Cardiology* 2012; 9: 263-5.
13. **Choudhry NK**, Liao J, Detsky AS. Selecting a specialist: adding evidence to the clinical practice of making referrals. *Journal of the American Medical Association* 2014; 312: 1861-1862.
14. Lauffenburger JC, **Choudhry NK**. Text messaging and patient engagement in an increasingly mobile world. *Circulation* 2016; 133(6): 555-556.
15. Bateman BT, **Choudhry NK**. Limiting the Duration of Opioid Prescriptions: Balancing Excessive Prescribing and the Effective Treatment of Pain. *JAMA Internal Medicine*. Published online April 04, 2016. doi:10.1001/jamainternmed.2016.0544.

### Book Chapters

1. Choudhry S, **Choudhry NK**, Brown AD. The legal regulation of referral incentives: physician kickbacks and physician self-referral under provincial rules of physician professional misconduct. In: Flood C, editor. The Frontiers of Fairness. Toronto: University of Toronto Press; 2006. p261-281.
2. **Choudhry NK**. Diagnostic decision making. In: Pistoria M, Amin A, Dressler D, McKean S, Budnitz T. Core competencies in hospital medicine: development and methodology. *Journal of Hospital Medicine* 2006; 1: (Suppl 1): 65-66.
3. **Choudhry NK**. Value-based insurance designs and healthcare spending. In: Yong PL, Saunders RS, Olsen L, eds. The Healthcare Imperative: Lowering Costs and Improving Outcomes. Washington, DC: The National Academies Press; 2010. p380-386.
4. Antman EM, Califf RM, **Choudhry NK**. Tools for assessment of cardiovascular tests and therapies. In: Antman EM, editor. Cardiovascular Therapeutics - A Companion to Braunwald's Heart Disease, 4th Edition. Philadelphia: Elsevier Saunders; 2012.

5.

(b) (4)

### Books

1.

(b) (4)

### **Professional Educational Materials or Reports**

1. **Choudhry NK**. Holding down the over-treatment of nausea and emesis. Brigham and Women's Hospital, 2005.
2. **Choudhry NK**. The rational use of G-CSF in patients with febrile neutropenia. Brigham and Women's Hospital, 2006.
3. **Choudhry NK**, Avorn J. Sticking to the evidence for antiplatelet drugs. Independent Drug Information Service; 2006: available at: [www.rxfacts.org](http://www.rxfacts.org). Update published 2009.
4. **Choudhry NK**, Shrank WH. How low should you go?: a practical review of current data on lipid lowering. Independent Drug Information Service; 2006: available at: [www.rxfacts.org](http://www.rxfacts.org). Update published 2010.
5. **Choudhry NK**, Fischer MA, Shrank WH. Controlling the hypertension epidemic: regimens with the best efficacy, tolerability and affordability," Independent Drug Information Service; 2007: available at: [www.rxfacts.org](http://www.rxfacts.org).
6. **Choudhry NK**, Fischer MA, Shrank WH. A spoon full of medicine helps the sugar go down: improving the management of Type 2 Diabetes, Independent Drug Information Service; 2007: available at: [www.rxfacts.org](http://www.rxfacts.org).
7. **Choudhry NK**, Fischer MA, Shrank WH, Avorn JA. . The Pursuit of Happiness: Management of Depression in the Elderly, Independent Drug Information Service; 2008: available at: [www.rxfacts.org](http://www.rxfacts.org).
8. **Choudhry NK**, Scheurer D. Did ACCORD show discord on how to manage BP and lipids in diabetic patients? Not totally. Independent Drug Information Service; 2010: available at: [www.rxfacts.org](http://www.rxfacts.org).
9. **Choudhry NK**, Scheurer D. Do proton pump inhibitors (PPIs) cause fractures? Independent Drug Information Service; 2010: available at: [www.rxfacts.org](http://www.rxfacts.org).
10. **Choudhry NK**, Scheurer D, Avorn J. Do calcium supplements increase cardiovascular risk? Independent Drug Information Service; 2010: available at: [www.rxfacts.org](http://www.rxfacts.org).
11. **Choudhry NK**, Scheurer D. Now what for patients taking rosiglitazone (Avandia)? Independent Drug Information Service; 2011: available at: [www.rxfacts.org](http://www.rxfacts.org).

12. **Choudhry NK**, Scheurer D. Long-acting bronchodilators in COPD: making the right choice. Independent Drug Information Service; 2011: available at: [www.rxfacts.org](http://www.rxfacts.org).
13. **Choudhry NK**, Scheurer D, Avorn J. Rethinking the role of simvastatin: recent actions from the FDA. Independent Drug Information Service; 2011: available at: [www.rxfacts.org](http://www.rxfacts.org).
14. **Choudhry NK**, Scheurer D, Avorn J. Bad AIM? A stopped trial raises questions about niacin use. Independent Drug Information Service; 2011: available at: [www.rxfacts.org](http://www.rxfacts.org).
15. **Choudhry NK**, Huntington I. Can an azithro a day keep COPD exacerbation away? Independent Drug Information Service; 2012: available at: [www.rxfacts.org](http://www.rxfacts.org).
16. Scheurer D, **Choudhry NK**. New and improved? Oral anticoagulants to reduce stroke in atrial fibrillation. Independent Drug Information Service; 2012: available at: [www.rxfacts.org](http://www.rxfacts.org).
17. **Choudhry NK**, Fischer MA, Avorn JL, Jackowski. Type 2 diabetes: Just a spoonful of medicine helps the sugar go down: Improving the management of Type 2 Diabetes. Independent Drug Information Service; 2013: available at: [www.rxfacts.org](http://www.rxfacts.org).
18. **Choudhry NK**, Desai NR. Aggregating the evidence on antiplatelet drugs: a review of recent clinical trials. Independent Drug Information Service; 2013: available at [www.rxfacts.org](http://www.rxfacts.org)
19. Jackowski L. Acid suppression therapy: neutralizing the hype. Avorn J, **Choudhry NK**, Fischer M, editors. Independent Drug Information Service; 2012: available at [www.rxfacts.org](http://www.rxfacts.org)
20. Scheurer D. Antipsychotic medications in primary care: limited benefit, sizeable risk. Osser D, Avorn J, **Choudhry NK**, Fischer M, consultants. Independent Drug Information Service; 2013: available at [www.rxfacts.org](http://www.rxfacts.org)
21. Scheurer D. A guide to outpatient management of congestive heart failure. Avorn J, **Choudhry NK**, Fischer M, editors. Independent Drug Information Service; 2013: available at [www.rxfacts.org](http://www.rxfacts.org)
22. Braun S. Helping patients with COPD breathe easier: integrating the latest evidence on chronic lung disease into primary care practice. Avorn J, **Choudhry NK**, Fischer M, Hurley E, editors. Independent Drug Information Service; 2013: available at [www.rxfacts.org](http://www.rxfacts.org)
23. Braun S. Evaluation and management of Alzheimer's disease and related disorders. Avorn J, **Choudhry NK**, Fischer M, Hurley E, Dancel E, editors. Independent Drug Information Service; 2014: available at [www.rxfacts.org](http://www.rxfacts.org)
24. Braun S. Preventing overuse of antipsychotic drugs in nursing home care: safer alternatives. Avorn J, **Choudhry NK**, Fischer M, Hurley E, editors. Independent Drug Information Service; 2014: available at [www.rxfacts.org](http://www.rxfacts.org)
25. Braun S. Preventing falls in the elderly: what primary care clinicians can do to reduce injury and death. Avorn J, **Choudhry NK**, Fischer M, Hurley E, editors. Independent Drug Information Service; 2014: available at [www.rxfacts.org](http://www.rxfacts.org)
26. Plank R. Human immunodeficiency virus infection and acquired immunodeficiency: what the primary care physician should know about diagnosis and management. Avorn J, **Choudhry NK**, Fischer M, Scheurer D, editors. Independent Drug Information Service; 2014: available at [www.rxfacts.org](http://www.rxfacts.org)
27. **Choudhry NK**, Fischer MA, Avorn JL, Jackowski L. Type 2 diabetes: Just a spoonful of medicine helps the sugar go down: improving the management of Type 2 Diabetes. Independent Drug Information Service; 2013: available at: [www.rxfacts.org](http://www.rxfacts.org).
28. Uhlig K, Block J. Weighing the evidence on obesity and its management. Cohen P, **Choudhry NK**, Fischer M, Avorn J, Hurley E, editors. Independent Drug Information Service; 2014: available at [www.rxfacts.org](http://www.rxfacts.org)

## Thesis

**Choudhry NK**. The impact of physician factors on health care quality [PhD Dissertation]. Cambridge (MA): Harvard University; 2005.